Lupus & Connective Tissue Diseases
From the Journals
Rheumatologic disease activity an important influencer of COVID-19 death risk
COVID-19 Global Rheumatology Alliance physician registry data highlight need to maintain adequate disease control to lower risk for death from...
From the Journals
Meta-analysis finds much less lupus than expected
Prevalence far higher among women than men, with Native Americans and Blacks disproportionately burdened.
From the Journals
Palliative care underused in pulmonary arterial hypertension
Independent predictors of palliative care services for PAH patients included White race, higher socioeconomic status, and private insurance.
News from the FDA/CDC
FDA approves voclosporin for lupus nephritis
The calcineurin inhibitor is the first oral treatment to be approved for lupus nephritis.
From the Journals
Severe renal arteriosclerosis may indicate cardiovascular risk in lupus nephritis
Statins were underused in a lupus nephritis cohort regardless of arteriosclerosis severity.
From the Journals
Treprostinil offers some benefits for patients with ILD-associated pulmonary hypertension
The INCREASE trial was multicenter, randomized, double blind, and placebo controlled.
From the Journals
Ehlers-Danlos syndrome associated with various complications in hospitalized patients
“This study legitimizes what many who take care of patients with EDS know to be true, and for those who don’t, it brings a lot of attention to...
From the Journals
High hydroxychloroquine blood level may lower thrombosis risk in lupus
Longitudinal measurement of hydroxychloroquine blood levels may help to develop personalized dosing strategies.
Guidelines
EULAR recommendations define strategies to improve adherence in RMDs
A task force put together four overarching principles and nine points to consider to address adherence to both pharmacologic and nonpharmacologic...
Recap
Preserving kidney function in patients with lupus nephritis
Lupus nephritis treatment goals include reducing serologic activity, preventing long-lasting kidney damage,...
News from the FDA/CDC
FDA expands belimumab indication to adults with lupus nephritis
The approval is based on the BLISS-LN trial, in which belimumab, when added to standard therapy, increased response rates and prevented worsening...